HFE Hemochromatosis: One Genotype, Two Very Different Diseases
Two related patients, the identical hereditary hemochromatosis genotype. The disagreement isn't about the mutation — it's about whether a genotype that hasn't become disease should be treated as though it already has.
Gerald K. is the reason his younger cousin Simone knows her own genetic risk at all — his diagnosis prompted the family cascade-testing recommendation that found her identical genotype months later. He wound down his accounting practice to three clients last year, planning to close it entirely once his younger client's tax season ends, and has spent the extra time noticing things he'd been too busy to track before — joint aches in both hands and second and third metacarpophalangeal joints specifically, which he'd chalked up to age, and a new diabetes diagnosis six months ago that surprised him given his otherwise unremarkable weight and generally active retirement routine.
A workup for the joint pain led to iron studies that came back strikingly abnormal: ferritin 850, transferrin saturation 78 percent, and genetic testing confirming C282Y homozygosity for hereditary hemochromatosis. His skin has also taken on a subtle bronze cast his wife noticed before he did, the classic if now uncommonly seen cutaneous sign of significant iron deposition.
A liver elastography ordered the same week showed early fibrosis, consistent with genuine iron-mediated organ injury rather than an incidental genetic finding, and his cardiac exam and echocardiogram remain reassuringly normal, meaning his heart hasn't yet accumulated the iron burden that eventually threatens conduction and contractile function in untreated disease. This is not a borderline case, and it is worth being precise about why. Allen and colleagues, reporting the HealthIron cohort in the New England Journal of Medicine in 2008, defined iron-overload-related disease as documented iron overload plus at least one of cirrhosis, liver fibrosis, hepatocellular carcinoma, raised aminotransferases, symptomatic hemochromatosis, or arthropathy of the second and third metacarpophalangeal joints. Gerald meets that definition twice over, on the fibrosis and on the joints his own history named — he is not a genotype at risk of disease, he is inside the case definition.
Case A: Genotype that has already become disease
This is a clear indication for therapeutic phlebotomy, and I'd start now rather than wait for further confirmation. His genotype, ferritin, transferrin saturation, and objective fibrosis all point the same direction — real organ involvement from iron overload, not an incidental genetic finding that happens to coexist with unrelated joint pain and diabetes.
The target is a ferritin under 50, achieved through weekly phlebotomy initially and titrated down once he approaches goal — a standard, well-established protocol for penetrant disease like his.
I agree with starting phlebotomy immediately, and want to add that his new diabetes shouldn't be managed as a separate, unrelated diagnosis — pancreatic iron deposition is a plausible contributor, and there's real precedent for glycemic control improving as iron burden comes down with phlebotomy, though not in every patient.
I wouldn't withhold standard diabetes therapy while waiting to see if phlebotomy alone helps his glucose control — the two should proceed in parallel, not sequentially.
Agreed: weekly therapeutic phlebotomy started immediately, targeting ferritin under 50, with diabetes management continued in parallel rather than deferred.
Simone D. learned she carries the same C282Y homozygous genotype as her cousin Gerald only because his diagnosis prompted a family cascade-testing recommendation neither of them had heard of before his own workup — she works three afternoons a week at a flower shop near her apartment, a schedule she chose deliberately to leave mornings free for her graduate coursework in library science, and had no symptoms and no reason to suspect anything before the test came back — no joint pain, no fatigue, no skin changes, and regular menstrual cycles that, unbeknownst to her, have been doing real physiologic work for two decades.
Her own iron studies tell a genuinely different story than his: ferritin 280, only mildly elevated, transferrin saturation 52 percent, and entirely normal liver enzymes with no fibrosis on elastography. Her fasting glucose and cardiac exam are both unremarkable as well, with none of the multi-organ picture that brought Gerald's diagnosis to light in the first place.
The penetrance data are what separate her from her cousin, and they separate them by sex rather than by genotype. In the same HealthIron cohort, iron-overload-related disease was documented in twenty-eight percent of male C282Y homozygotes and in one of eighty-four women — 1.2 percent. Two decades of menstrual iron loss are the most plausible reason she sits in the second figure rather than the first, which also means the protection is not permanent: a Newfoundland cohort followed for more than a decade found penetrance in postmenopausal women climbing back toward the male rate. Her genetic counselor framed the result as a real risk factor worth monitoring rather than a diagnosis she already has, and the monitoring interval that matters most is the one that starts when her periods stop.
Case B: The same genotype, no disease yet
I wouldn't start phlebotomy on her today. Her ferritin is only mildly elevated, her liver studies and elastography are normal, and C282Y homozygosity is well documented to have incomplete penetrance — a meaningful proportion of homozygotes, especially women with a long menstrual history, never accumulate iron the way her cousin did. Watchful waiting with annual iron studies is a reasonable, evidence-consistent plan here.
This isn't a claim she'll never need treatment — her menopause could change that calculation meaningfully, since she'll lose the physiologic iron loss that has likely protected her so far.
I'd agree with watchful waiting for now, but want her menopausal transition flagged explicitly as the point to reassess more aggressively, not left as an incidental footnote — losing menstrual iron loss is exactly the kind of change that could unmask penetrance that hasn't shown itself yet.
I wouldn't start prophylactic phlebotomy preemptively in anticipation of menopause either — that would treat a genotype, not a disease, which is the opposite error from undertreating her cousin would have been.
Agreed: watchful waiting with annual ferritin and transferrin saturation, no phlebotomy started now.
Not agreed: exactly how her monitoring should intensify around menopause — the hematologist favored reflexively shortening her check interval at that point, while the endocrinologist preferred waiting for an actual ferritin trend upward before changing anything, to avoid treating an anticipated change rather than an observed one.